Welcome to our dedicated page for Guardian Pharmacy Services news (Ticker: GRDN), a resource for investors and traders seeking the latest updates and insights on Guardian Pharmacy Services stock.
Guardian Pharmacy Services, Inc. provides long-term care pharmacy services for residents of long-term health care facilities. The company partners with LTCFs through a locally based pharmacy model to dispense medications and deliver technology-enabled clinical and administration services intended to support drug-regimen adherence and reduce medication-administration errors.
Recurring GRDN news covers quarterly results and guidance, resident and prescription-volume trends, the effects of drug-pricing changes, healthcare conference presentations, and capital-structure activity involving Class A common stock. Company updates also reference its pharmacy network, facility relationships, and service categories across assisted living, behavioral health, group home, and other long-term care settings.
Guardian Pharmacy Services (NYSE: GRDN) reported strong Q1 2025 financial results, with revenue reaching $329.3 million, up 20% year-over-year. The company's resident count increased 15% to 189,000, while net income grew by $2.2 million to $9.3 million. Adjusted EBITDA rose 16% to $23.4 million.
The growth was driven by organic expansion and recent acquisitions, including Heartland Pharmacy and Freedom Pharmacy. Guardian completed another acquisition in Wichita, Kansas on April 1, 2025, bringing its total pharmacy count to 52. The company maintains a strong financial position with $14.0 million in cash and no long-term debt.
Guardian reaffirmed its 2025 guidance, expecting revenue between $1.330-1.350 billion and Adjusted EBITDA of $97-101 million.
Guardian Pharmacy Services (NYSE: GRDN), a leading long-term care pharmacy services provider, has appointed Ashley Stockton as Senior Director, Head of Investor Relations. Stockton brings nearly 30 years of equity markets experience, most recently serving as Head of Southeast Institutional Equity Sales at J.P. Morgan. Her background includes roles in equity research and investment banking.
In her new position, Stockton will lead investor relations strategy and act as the primary liaison with shareholders, analysts, and the investment community. CEO Fred Burke highlighted her extensive background in equity markets and experience advising institutional investors as key qualifications for the role. Stockton holds a BS from the University of Virginia's McIntire School of Commerce and serves on the Georgia Securities Association board.
Guardian Pharmacy Services (NYSE: GRDN), a leading long-term care (LTC) pharmacy services provider in the United States, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close.
The company will host a conference call at 4:30 pm ET to discuss the quarterly results. Investors and analysts can access the call through:
- Audio webcast: https://investors.guardianpharmacy.com
- U.S. participants dial-in: (646) 564-2877
- International participants dial-in: +1 (800) 549-8228
- Conference ID: "96083"
A replay of the call will be made available shortly after completion and will remain accessible for approximately 60 days.
Guardian Pharmacy Services (NYSE: GRDN) has announced the opening of a new pharmacy location in Columbus, Ohio, expanding its long-term care (LTC) pharmacy services across Ohio, Kentucky, and West Virginia. The new facility, operating as Guardian Pharmacy of Ohio, complements the existing Mullaney's Pharmacy operation in Cincinnati.
The 5,600-square-foot Columbus facility features state-of-the-art technology, automation, and a training center. Since joining Guardian in 2020, Mullaney's Pharmacy has tripled its resident service numbers in less than five years. Tom Mullaney, RPh, will lead both locations alongside Director of Operations Troy Stinson and Joshua Heiden as pharmacist-in-charge.
The expansion strengthens Guardian's presence in the region, serving assisted living, skilled nursing, behavioral health communities, and individuals with intellectual and developmental disabilities. Guardian Pharmacy Services has grown from a single location to 51 pharmacies across 38 states since its founding in 2004.
Guardian Pharmacy Services (NYSE: GRDN) has announced the opening of a new pharmacy in Naples, Florida, expanding its long-term care (LTC) pharmacy services in Southwest Florida. This addition complements their North Port location, enabling better service coverage from Sarasota to Lake Placid to Marco Island.
Guardian Pharmacy of Southwest Florida, established in 2014, has shown significant growth with a 15% annual increase in customer base over the past three years. The Naples location, led by Jay Mandra, PharmD, and Tiffany Fernandez, will enhance service delivery with faster delivery times and improved medication management for LTC communities.
The Naples facility becomes Guardian's eighth pharmacy in Florida, joining locations in Daytona, Jacksonville, Crestview, Orlando, Boca Raton, Tampa, and North Port. Since its founding in 2004, Guardian Pharmacy Services has expanded to 51 pharmacies across 38 states, utilizing a local management business model supported by a centralized Corporate Support Team.
Guardian Pharmacy Services (NYSE: GRDN) reported strong Q4 and full-year 2024 results. Q4 revenue reached $338.6 million, up 20% year-over-year, driven by organic growth and acquisitions of Heartland and Freedom Pharmacy. Resident count grew 14% to 186,000.
Q4 net income decreased to $11.8 million, while Adjusted EBITDA rose 30% to $25.9 million. For full-year 2024, revenue increased 17% to $1.228 billion, though the company recorded a net loss of $71.0 million, primarily due to $131.5 million in share-based compensation expense related to Corporate Reorganization and IPO.
The company ended 2024 debt-free with a $40 million available credit line, expandable to $75 million. For 2025, Guardian projects revenue of $1.330-1.350 billion and Adjusted EBITDA of $97.0-101.0 million, including $4.0 million in public company expenses.
Guardian Pharmacy Services (NYSE: GRDN) has released preliminary Q4 and FY2024 results, reporting strong performance. Q4 revenue reached $338.6 million, up 20.5% year-over-year, while resident count grew 14.1% to 186,000. The growth was driven by organic expansion and acquisitions of Heartland and Freedom Pharmacy.
FY2024 revenue climbed 17.4% to $1.228 billion, though net loss was between $71.8-72.8 million, primarily due to $131.5 million in share-based compensation related to Corporate Reorganization and IPO. Q4 net income is expected between $10.1-11.1 million.
For 2025, Guardian projects revenue of $1.330-1.350 billion and Adjusted EBITDA of $97.0-101.0 million. The company's performance was boosted by increased flu and COVID-19 vaccinations in long-term care facilities.
Guardian Pharmacy Services (NYSE: GRDN), a leading long-term care pharmacy services provider, has announced its participation in the Raymond James & Associates' 46th Annual Institutional Investors Conference. The event will take place in Orlando on March 3, 2025, featuring a company presentation at 9:50am ET.
Investors and interested parties can access the live audio webcast through the company's investor relations website at https://investors.guardianpharmacy.com. A replay of the presentation will be available on the same platform and will remain accessible until Guardian's Q1 2025 earnings release.
Guardian Pharmacy Services (NYSE: GRDN) announced a strategic partnership with Freedom Pharmacy, an independent long-term care pharmacy in Randolph, New Jersey. This marks Guardian's first venture into New Jersey, expanding its Mid-Atlantic footprint. Freedom Pharmacy, founded in 2022, serves over 1,300 residents across North, Northwest and Central New Jersey.
Linda Witzal will continue as president, and all current staff will remain employed, with plans to hire additional employees as the business grows. The partnership allows Freedom to maintain its local focus while accessing Guardian's national resources, including data analytics, HR, IT, and payor relations support.
Guardian Pharmacy Services, founded in 2004, has expanded to 50 pharmacies across 37 states through organic growth, greenfield startups, and acquisitions.
Guardian Pharmacy Services (NYSE: GRDN) reported Q3 2024 financial results with revenue of $314.4 million, up 20% year-over-year, driven by organic growth and the Heartland Pharmacy acquisition. The company's resident count increased 12% to 180,000. Despite revenue growth, Guardian reported a net loss of $105.8 million, primarily due to $122.4 million in share-based compensation expenses related to Corporate Reorganization and IPO. Adjusted EBITDA grew 20% to $23.0 million. The company provided full-year 2024 guidance projecting revenue between $1.205-1.215 billion and Adjusted EBITDA of $86.5-87.0 million.